JAMA: Effects of high-dose influenza vaccine on mortality and hospitalization risk of cardiopulmonary disease in people at high risk of cardiovascular disease

People with underlying cardiovascular diseases are flu-prone people, and influenza can lead to an increased incidence and risk of death from cardiopulmonary diseases in these populations, while the above-mentioned populations have a lower immune response response after influenza vaccination due to underlying diseases.
recently looked at the effects of increasing vaccination doses on reducing influenza-related hospitalizations associated with high-risk cardiovascular disease.
From September 2016 to January 2019, researchers studied 5,260 participants at 157 medical centers in the United States and Canada for up to three flu seasons, with recent hospitalizations for acute myocardial infarction or heart failure, and at least one additional risk factor.
participants were randomly given a high dose of trieth price (n-2630) or a standard dose of tri-price (n-2630) to inactivated influenza vaccine and repeatedly vaccinated for 3 flu seasons.
end of the study was total hospitalization for death or cardiopulmonary disease, while assessing vaccine-related adverse events.
participants had an average age of 65.5 years, 3,787 men and 3,289 had heart failure, 7,154 vaccinations had been given and 5,226 participants (99.4%) had completed the trial.
In the high-dose trialose vaccine group, 884 participants had 975 major endpoint events, of which 883 were hospitalized for cardiovascular or lung causes and 92 died, while in the standard dose trialic vaccine group, 837 participants had 924 major outcome events, of which 846 were hospitalized for cardiovascular or lung reasons, 78 died, and the intergroup risk ratio was 1.06.
1449 vaccine-related adverse reactions occurred in the high-dose group, 1229 cases in the standard dose group (40.5% vs 34.4%), 55 cases (2.1%) in the high-dose group and 44 cases (1.7%) in the standard group. The study of major endpoint differences between groups
concluded that for people with underlying cardiovascular disease, receiving a high dose of trialic inactivated influenza vaccine did not reduce the risk of influenza-related deaths and hospitalization for cardiopulmonary disease compared to the standard measured tri-inactivated influenza vaccine, but it was recommended that this population be vaccinated against influenza.
。